Search research articles
Contact Us
Filters
Showing results (61-70 of 77) with videos related to
Page
of 8
Sort By:
Diabetologia
|
April 7, 2019
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
Robert S Rosenson, Martha L Daviglus, Yehuda Handelsman, et al.
The American Journal of Cardiology
|
March 19, 2015
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia
Christie M Ballantyne, Joel Neutel, Anne Cropp, et al.
Journal of Medical Economics
|
April 21, 2026
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial
Erin Johansson, John P H Wilding, Navneet Upadhyay, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 2, 2015
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
Harold Bays, Daniel Gaudet, Robert Weiss, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery
|
November 28, 2022
Mesenteric fat cryolipolysis attenuates insulin resistance in the Ossabaw swine model of the metabolic syndrome
Rafi Mazor, Alex Babkin, Peter J Littrup, et al.
Lancet (London, England)
|
November 9, 2025
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Liana K Billings, Stanley Hsia, Harold Bays, et al.
Journal of the American College of Cardiology
|
April 3, 2014
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
Michael J Koren, Pernille Lundqvist, Michael Bolognese, et al.
Journal of Clinical Lipidology
|
December 3, 2010
Safety of extended-release niacin/laropiprant in patients with dyslipidemia
James McKenney, Harold Bays, Michael Koren, et al.
Obesity (Silver Spring, Md.)
|
April 12, 2007
Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss
Ngozi Erondu, Thomas Wadden, Ira Gantz, et al.
The New England Journal of Medicine
|
October 30, 2024
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Henning Bliddal, Harold Bays, Sébastien Czernichow, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 77) with videos related to
Sort By:
Page
of 8
Diabetologia
|
April 7, 2019
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
Robert S Rosenson, Martha L Daviglus, Yehuda Handelsman, et al.
The American Journal of Cardiology
|
March 19, 2015
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia
Christie M Ballantyne, Joel Neutel, Anne Cropp, et al.
Journal of Medical Economics
|
April 21, 2026
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial
Erin Johansson, John P H Wilding, Navneet Upadhyay, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 2, 2015
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
Harold Bays, Daniel Gaudet, Robert Weiss, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery
|
November 28, 2022
Mesenteric fat cryolipolysis attenuates insulin resistance in the Ossabaw swine model of the metabolic syndrome
Rafi Mazor, Alex Babkin, Peter J Littrup, et al.
Lancet (London, England)
|
November 9, 2025
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Liana K Billings, Stanley Hsia, Harold Bays, et al.
Journal of the American College of Cardiology
|
April 3, 2014
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
Michael J Koren, Pernille Lundqvist, Michael Bolognese, et al.
Journal of Clinical Lipidology
|
December 3, 2010
Safety of extended-release niacin/laropiprant in patients with dyslipidemia
James McKenney, Harold Bays, Michael Koren, et al.
Obesity (Silver Spring, Md.)
|
April 12, 2007
Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss
Ngozi Erondu, Thomas Wadden, Ira Gantz, et al.
The New England Journal of Medicine
|
October 30, 2024
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Henning Bliddal, Harold Bays, Sébastien Czernichow, et al.
Page
of 8